APRE APREA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, APREA THERAPEUTICS INC reported revenue of n/a, net income of −$3.59M and diluted EPS of −$0.07; for the fiscal year ended December 2025 revenue was n/a.
APRE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$13.2M, net income −$12.6M (margin n/a), EPS −$1.93
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$14.3M, net income −$13.0M (margin n/a), EPS −$2.35
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$15.5M, net income −$14.3M (margin n/a), EPS −$3.95
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$113M, net income −$113M (margin n/a), EPS −$67.99
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$37.4M, net income −$37.1M (margin n/a), EPS −$34.88
APRE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.59M, EPS −$0.07
- Quarter ended Mar 31, 2026: revenue n/a, net income −$3.29M, EPS −$0.22
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$2.46M, EPS −$0.27
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.97M, EPS −$0.47
- Quarter ended Jun 30, 2025: revenue n/a, net income −$3.24M, EPS −$0.53
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.93M, EPS −$0.66
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$2.89M, EPS −$0.46
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.78M, EPS −$0.64
- Quarter ended Jun 30, 2024: revenue n/a, net income −$3.47M, EPS −$0.58
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.81M, EPS −$0.67
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$3.44M, EPS −$0.88
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.20M, EPS −$0.86
- Quarter ended Jun 30, 2023: revenue n/a, net income −$3.26M, EPS −$0.87
- Quarter ended Mar 31, 2023: revenue n/a, net income −$4.38M, EPS −$1.34
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$2.44M, EPS $28.30
- Quarter ended Sep 30, 2022: revenue n/a, net income −$4.02M, EPS −$2.32
- Quarter ended Jun 30, 2022: revenue n/a, net income −$98.3M, EPS −$86.72
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.94M, EPS −$7.25
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$7.76M, EPS −$33.49
- Quarter ended Sep 30, 2021: revenue n/a, net income −$9.45M, EPS −$0.45
APRE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$13.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$12.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$25.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$37.7M, share buybacks n/a
APRE balance sheet
- Jun 30, 2026: cash $41.2M, total assets $42.3M, total liabilities n/a, shareholders' equity $38.5M
- Mar 31, 2026: cash $46.5M, total assets $47.6M, total liabilities n/a, shareholders' equity $41.6M
- Dec 31, 2025: cash $14.6M, total assets $15.9M, total liabilities n/a, shareholders' equity $12.4M
- Sep 30, 2025: cash $13.7M, total assets $14.3M, total liabilities n/a, shareholders' equity $10.9M
- Jun 30, 2025: cash $16.5M, total assets $17.3M, total liabilities n/a, shareholders' equity $13.4M
- Mar 31, 2025: cash $19.3M, total assets $20.2M, total liabilities n/a, shareholders' equity $15.5M
- Dec 31, 2024: cash $22.8M, total assets $24.0M, total liabilities n/a, shareholders' equity $19.3M
- Sep 30, 2024: cash $26.2M, total assets $26.9M, total liabilities n/a, shareholders' equity $21.9M
Is APRE profitable?
No. APREA THERAPEUTICS INC lost $12.3M over the last four quarters.
What is APRE's EPS?
Diluted earnings per share over the last four quarters were −$1.03; −$0.07 in the latest quarter.